A recent study showed that grade II meningiomas are molecularly heterogeneous and, based on the mutational status of NF2, TERT promoter, TP53, BAP1, PRBM1, AKT1, SMO and PIK3CA, they can be subgrouped into three different categories, each characterized by peculiar clinical-pathological features [9]. This evidence concerns the gene TERT and meningioma.